Navigation Links
A Novel Oral Anticoagulant is Planned to be Developed for Patients with Prosthetic Heart Valves or Chronic Renal Dysfunction
Date:3/8/2013

tic variant of this enzyme.

"Tecarfarin was specifically designed not to be metabolized by any CYP enzymes, which means it may require less monitoring than warfarin. Some monitoring, according to experts, may still be needed to ensure patient compliance. Data from EMBRACE-AC trial showed that tecarfarin is a more effective OAC than warfarin in patients with a CYP2C9 genetic variant taking at least one CYP2C9 inhibitor despite close monitoring," said Dr Peter Milner , Executive Chairman of Armetheon and partner at AshHill Pharmaceutical Investments.  He added, "for approval of tecarfarin, we anticipate only one more pivotal clinical trial will be required which could be a 'real world', open label study involving about 2500 pre-defined patients."

Recent research indicates that patients with chronic renal dysfunction or failure have reduced or variable activity of CYP enzymes such as CYP2C9 and CYP3A4 as well as the transporter permeability glycoprotein (P-gp). This may explain warfarin's suboptimal performance in this patient population. Currently marketed novel non-monitored OACs (in particular, Factor Xa inhibitors) are eliminated via the kidney and most of them are metabolized via CYP3A4 enzymes in addition to interacting with the P-gp. This may explain the significant variability in anticoagulation response to the novel non-monitored OACs in patients with chronic renal dysfunction or failure.

"Genetic and other sources of variability in the drug metabolizing enzymes CYP3A4 and CYP2C9 or transport related proteins such a P-gp could lead to unpredictable variability in plasma levels of drugs that are metabolized/eliminated through these pathways, particularly if they are used with concomitant medications that may be inhibitors of these metabolic/elimination pathways," said Professor Leslie Z. Benet , former Chairman and Professor of Biopharmaceutical Sciences at University of
'/>"/>

SOURCE Armetheon, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
2. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
3. Upcoming Presentations on Global Market Access Issues and Trends in Health Economics and Outcomes Research at ISPOR 2012 by Novel Health Strategies
4. Scripps Doctors Study Novel New Device to Diagnose Irregular Heart Beat
5. Novelos Therapeutics Successfully Completes First Cohort In Phase 1b Solid Tumor Trial With I-131-CLR1404 (HOT) Cancer-Targeted Molecular Radiotherapeutic
6. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
7. New Data Support Role of Prometheus Laboratories Novel Assay in Optimizing IBD Treatment Management
8. Stiefel, a GSK company, enters agreement with Welichem Biotech, Inc. to acquire a novel topical agent for psoriasis and atopic dermatitis
9. Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102
10. OICR funds Fluorinov Pharma Inc. to further develop its novel drug for the treatment of blood cancers
11. CSL Behring Receives FDA Orphan Drug Designation for rIX-FP, a Novel Therapy in Development to Treat Congenital Factor IX Deficiency (Hemophilia B)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... On Thursday, July 10, 2014, the NASDAQ ... Average finished the day 0.42% lower at 16,915.07, and the ... broad based as eight out of ten sectors ended the ... ended the day at 711.88, down 0.02%, while the index ... initiated coverage on the following equities: Covidien PLC (NYSE: ...
(Date:7/11/2014)... , July 11, 2014 Research ... addition of the "Immunoprotein Diagnostic Testing Market ... the highest CAGR of 6% and is expected ... report to their offering. ... immunoprotein diagnostic testing has been segmented according to ...
(Date:7/11/2014)... LONDON , July 11, 2014 /PRNewswire/ ... of visitors to Safety & Health Expo ... by the move to London ... senior management attending exhibition.     ... (Photo: http://photos.prnewswire.com/prnh/20140711/696892-a ) ...
Breaking Medicine Technology:Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 2Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 3Health Care Equipment Equities Movers and Shakers -- Research on Covidien, Baxter, DexCom, and Boston Scientific 4Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4
... NoviPet , a leading global provider of ... supplements for dogs at the Backer,s 24th Annual Pet Industry ... 2012, in Atlantic City, New Jersey. The new dietary ... City Convention Center. NoviPet intends to widen its offerings in the ...
... Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) (the "Company" ... Distribution Specialists, LLC ("HDS") are pleased to announce that ... ("Agreement") with a major pro sports team based in ... of Clotamin.  The Agreement is part of new marketing ...
Cached Medicine Technology:NoviPet to Present New Food Supplements for Dogs at Pet Industry Spring Trade Show 2Sunpeaks Ventures Signs Advertising and Promotion Agreement With Another Major Sports Team - Clotamin To Be Sold at All Walgreens Locations Throughout Arizona 2Sunpeaks Ventures Signs Advertising and Promotion Agreement With Another Major Sports Team - Clotamin To Be Sold at All Walgreens Locations Throughout Arizona 3
(Date:7/14/2014)... Encino, CA (PRWEB) July 14, 2014 ... Dental Group is now offering Lumineers and ... more extensive procedures that require more preparation and greater ... use porcelain tooth-shaped shells to conceal visible flaws on ... Dr. Sabbagh-Fard work closely with patients to ensure they ...
(Date:7/14/2014)... Barbara Bronson Gray ... News) -- New research suggests that a faltering sense ... disease, and that an inexpensive, low-tech smell test could ... In two different studies, the decreased ability to identify ... function and progression to Alzheimer,s disease. "We,re trying ...
(Date:7/14/2014)... Kathleen Doheny HealthDay ... Losing a spouse may be linked to multiple health issues, ... study. For certain seniors, widowhood may even delay dementia, ... memory problem, losing the spouse was associated with a later ... married," said study researcher Dr. Bryan Woodruff. Woodruff, ...
(Date:7/14/2014)... Connecticut (PRWEB) July 14, 2014 ... is celebrating its Grand Opening on Monday, July ... Connecticut 06830. The celebration will last all week ... all new patients. Everyone is welcomed to attend. ... M.D. who provides physician-administered skincare, anti-aging, weight loss ...
(Date:7/14/2014)... Many people are unhappy with their ... to reduce a “double chin.” A new product ... to go under the knife. Jawflex is a double ... therefore tightening the skin in that area and reducing ... used for facial exercise, double chin elimination and sagging ...
Breaking Medicine News(10 mins):Health News:Encino Esthetic Dental Group is Now Offering Lumineers and Porcelain Veneers 2Health News:Could a Simple Smell Test Help Spot Alzheimer's Early? 2Health News:Could a Simple Smell Test Help Spot Alzheimer's Early? 3Health News:Widowhood May Delay Dementia in Some Seniors, Study Finds 2Health News:Widowhood May Delay Dementia in Some Seniors, Study Finds 3Health News:The Cosmetic Medic Announces Grand Opening of New Skin M.D., a Physician-Administered Anti-aging, Skincare, and Weight Loss Practice 2Health News:The Cosmetic Medic Announces Grand Opening of New Skin M.D., a Physician-Administered Anti-aging, Skincare, and Weight Loss Practice 3Health News:Jawflex | Double Chin Exercise for Double Chin Reduction 2
... BOSTON, Aug. 6 The Center for Business Intelligence (CBI), a ... which includes Dr. Paul Tang, Vice President and Chief Medical Information ... inaugural Access Federal Stimulus Incentives for Electronic Health Records ... in Alexandria, VA, on September 24-25, 2009. , ...
... unaware there is no cure, survey finds , THURSDAY, Aug. ... mistakenly believe that daily medicine can be taken to prevent ... a widespread lack of knowledge and awareness about food allergy ... adults also found that nearly half of respondents incorrectly believed ...
... , , , , ... Wyse Technology , the global leader in thin computing and ... . Kool Smiles is a rapidly-growing company whose mission is ... Since opening its first office in 2002 in Atlanta, GA, the ...
... , , HOUSTON, ... first patient in a Phase I/II clinical trial of BP-GMAX-CD1, a ... cancer. The disease-specific trial is being conducted under a Bellicum Investigational ... anticipates reporting initial results of the study in 2010. , ...
... MCLEAN, Va., Aug. 6 Sunrise Senior Living, Inc. ... data for the second quarter of 2009. Sunrise will host ... a.m. ET, to discuss the financial results. , , ... of progress in expense controls. In recent weeks we have seen ...
... Greece, August 6 , - Not for Release, Publication or Distribution ... Canada, Australia, South Africa or Japan or, any Other ... Unlawful, - This Announcement is not a Prospectus and is not ... Offer to buy any Securities in the United States or, ...
Cached Medicine News:Health News:CBI Announces the Agenda for Their Upcoming Access Federal Stimulus Incentives for Electronic Health Records Conference 2Health News:Food Allergy Facts Need More Focus 2Health News:Kool Smiles Relies on Wyse Technology Virtual Clients to Improve Patient Care and Security of Electronic Health Records (EHRs) 2Health News:Kool Smiles Relies on Wyse Technology Virtual Clients to Improve Patient Care and Security of Electronic Health Records (EHRs) 3Health News:Kool Smiles Relies on Wyse Technology Virtual Clients to Improve Patient Care and Security of Electronic Health Records (EHRs) 4Health News:Kool Smiles Relies on Wyse Technology Virtual Clients to Improve Patient Care and Security of Electronic Health Records (EHRs) 5Health News:Bellicum Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of Novel Vaccine for Patients With Advanced Prostate Cancer 2Health News:Bellicum Pharmaceuticals Announces Initiation of Phase I/II Clinical Trial of Novel Vaccine for Patients With Advanced Prostate Cancer 3Health News:Sunrise Reports Financial Results for Second-Quarter 2009 2Health News:Sunrise Reports Financial Results for Second-Quarter 2009 3Health News:Sunrise Reports Financial Results for Second-Quarter 2009 4Health News:Sunrise Reports Financial Results for Second-Quarter 2009 5Health News:Sunrise Reports Financial Results for Second-Quarter 2009 6Health News:Sunrise Reports Financial Results for Second-Quarter 2009 7Health News:Sunrise Reports Financial Results for Second-Quarter 2009 8Health News:Sunrise Reports Financial Results for Second-Quarter 2009 9Health News:Sunrise Reports Financial Results for Second-Quarter 2009 10Health News:Sunrise Reports Financial Results for Second-Quarter 2009 11Health News:Sunrise Reports Financial Results for Second-Quarter 2009 12Health News:Sunrise Reports Financial Results for Second-Quarter 2009 13Health News:Sunrise Reports Financial Results for Second-Quarter 2009 14Health News:Sunrise Reports Financial Results for Second-Quarter 2009 15Health News:Sunrise Reports Financial Results for Second-Quarter 2009 16Health News:Sunrise Reports Financial Results for Second-Quarter 2009 17Health News:Sunrise Reports Financial Results for Second-Quarter 2009 18Health News:Sunrise Reports Financial Results for Second-Quarter 2009 19Health News:Sunrise Reports Financial Results for Second-Quarter 2009 20Health News:EANS-News: Alapis Announces its Share Capital Increase to Raise c. EUR 451.1 million 2Health News:EANS-News: Alapis Announces its Share Capital Increase to Raise c. EUR 451.1 million 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: